KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Acadia Pharmaceuticals (ACAD) Accumulated Depreciation & Amortization (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 14 years of Accumulated Depreciation & Amortization data on record, last reported at $10.2 million in Q4 2024.

  • For Q4 2024, Accumulated Depreciation & Amortization rose 6.92% year-over-year to $10.2 million; the TTM value through Dec 2024 reached $10.2 million, up 6.92%, while the annual FY2024 figure was $10.2 million, 6.92% up from the prior year.
  • Accumulated Depreciation & Amortization reached $10.2 million in Q4 2024 per ACAD's latest filing, up from $9.6 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $10.2 million in Q4 2024 and bottomed at $3.9 million in Q4 2020.
  • Average Accumulated Depreciation & Amortization over 5 years is $7.6 million, with a median of $8.1 million recorded in 2022.
  • Peak YoY movement for Accumulated Depreciation & Amortization: fell 25.96% in 2020, then surged 56.64% in 2021.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $3.9 million in 2020, then soared by 56.64% to $6.2 million in 2021, then soared by 30.93% to $8.1 million in 2022, then grew by 18.02% to $9.6 million in 2023, then rose by 6.92% to $10.2 million in 2024.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $10.2 million in Q4 2024, $9.6 million in Q4 2023, and $8.1 million in Q4 2022.